Z_Smith ,- yes our competition , Ibalizumab ,

Z_Smith ,-

yes our competition , Ibalizumab , CD4 inhibitor .

I will just say few things about HIV treatment here , first , price with Ibalizumab is 118,000.00 a year plus ( my understanding ) IV treatment ..with more side effects than with Leronlimb .....

IV treatment every two weeks ..
They do not consider mono , only combo ...and no candidate for PrEP ...

I exchanged few e-mails couple of years ago with Dr Chen from TaiMed ...
and that what he told me about mono ...

In phase 3 , they had 40 patients , one drop out because of Immune Reconstitution Inflammatory Syndrome ..

There were deaths during treatment all together , not necessary due to Ibalizumab . ...

After study were finished , it was approved for MDR -3 as every 2 weeks IV treatment , with efficacy of 43%

We are much better in my opinion ,

We had in our combo study ( 50 or 52 patients ) ....MDR-3 patients , and MDR-2 without choices ,
none of our patients died or dropped from the study,
and our efficacy is 81% with 350 mg , and not one serious side effect...

And treatment is SC and not IV, very , very big difference to patients..
and 81% efficacy with 350 mg , is much better than 43% ...

Personally for R5 HIV strain HIV , I don't believe Ibalizumab is really a big competition to Leronlimab ...



All IMO.